Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET

Vaccine. 2022 Dec 12;40(52):7640-7645. doi: 10.1016/j.vaccine.2022.10.089. Epub 2022 Nov 7.

Abstract

Purpose: To evaluate the temporal evolution of vaccination against COVID-19 in a Swiss oncological cohort.

Methods: History of complete vaccination (i.e. at least two vaccine doses) against COVID-19 of patients undergoing oncological 18F-FDG PET/CT between February and September 2021 (n = 2613) was taken. Vaccination rate was compared with age-matched national data from the Swiss Federal Office of Public Health. Subgroup differences in temporal evolution of vaccination rate were analyzed by fitting a generalized linear model and determined by significant interaction between, sex, oncological diagnosis, and month of examination.

Results: Rate of complete vaccination against COVID-19 steadily increased and reached 81 % in September 2021. The fraction of vaccinated patients in the oncological cohort was higher in the beginning and approached the fraction in the age-matched general Swiss population at the end of the study period. Month of exam (p < 0.001) was the only significant predictor of the vaccination rate.

Conclusion: Vaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021. Compared to the age-matched general population it was higher in the beginning and similar by the end of the study period. Ethics approval: Trial registration: BASEC 2021-00444, Ethikkommission Zürich (Cantonal Ethics Committee Zurich), Switzerland, registered February 24th 2021.

Keywords: COVID-19; Cancer; Fluordeoxyglucose; Oncological Imaging; Vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Fluorodeoxyglucose F18*
  • Humans
  • Positron Emission Tomography Computed Tomography
  • Vaccination

Substances

  • Fluorodeoxyglucose F18
  • COVID-19 Vaccines